Tecentriq in combination with Avastin is the first and only cancer immunotherapy regimen approved for the treatment of unresectable or metastatic hepatocellular carcinoma.
Read more– Tecentriq’s fourth indication in metastatic non-small cell lung cancer and fifth indication in lung cancer overall – – Approval
Read more
Genentech’s Tecentriq’s First Phase III cancer immunotherapy study to show an improvement in overall survival and progression-free survival for the
Read more– IMvigor130 is the first positive Phase III study of a cancer immunotherapy combination in people with previously untreated advanced
Read more– Phase III IMpower110 study showed Tecentriq monotherapy helped people with advanced non-small cell lung cancer (NSCLC) with high PD-L1
Read more
Roche’s study met a goal, comparing a lung cancer therapy Tecentriq with cisplatin and pemetrexed as the initial monotherapy compared in advanced non-squamous and squamous non-small cell lung cancer (NSCLC) without ALK or EGFR mutations (Wild-Type or WT).
Read more
– IMvigor130 is the first positive Phase III study of a cancer immunotherapy combination in previously untreated advanced bladder cancer
Read more
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY),today announced that the U.S. Food and Drug Administration (FDA)approved Tecentriq® (atezolizumab), in combinationwith carboplatin and etoposide (chemotherapy), for the initial(first-line) treatment of adults with extensive-stage small cell lungcancer (ES-SCLC).
Read more
Roche said Monday it got accelerated approval to Tecentriq plus chemotherapy for the treatment of adults with unresectable triple-negative breast cancer (TNBC) in people whose tumours express PD-L1, as determined by an FDA-approved test.
Read moreSyndax Pharmaceutical expects the coming months to be a very exciting, milestone-rich, said Briggs W. Morrison, M.D., Chief Executive Officer of Syndax, in a press release Thursday, reporting financial results, fourth quarter ended December 31, 2018.
Read more